Hans Lee, MD

Dr. Hans Lee and Dr. Douglas Sborov discuss how clinicians conceptualize the three major BCMA-directed treatment approaches in relapsed/refractory multiple myeloma: CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.

The discussion opens with an overview of the rapidly evolving treatment landscape in relapsed/refractory multiple myeloma, highlighting the expanding range of BCMA-directed therapeutic approaches.

The panel looks ahead to the next 3 to 5 years of multiple myeloma treatment, highlighting emerging strategies that could further reshape the treatment landscape.

Dr. Hans Lee and Dr. Prashant Kapoor discuss strategies to expand access to CAR T-cell therapies and bispecific antibodies for patients with multiple myeloma, particularly in community oncology settings.

Dr. Hans Lee and Dr. Muhamed Baljevic discuss the emerging role of bispecific antibodies in frontline treatment for newly diagnosed multiple myeloma, focusing on data from the MajesTEC-5 study and other ongoing investigations.

Dr. Hans Lee and Dr. Prashant Kapoor discuss the potential role of talquetamab-based therapy in the evolving treatment sequence for relapsed/refractory multiple myeloma.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss treatment strategies for patients with multiple myeloma who relapse following BCMA-directed CAR T-cell therapy or bispecific antibodies.

Dr. Hans Lee, Dr. Prashant Kapoor, and Dr. Muhamed Baljevic discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, including its use across transplant-eligible and transplant-ineligible populations.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss supportive care considerations for patients receiving T-cell redirecting therapies, with a focus on infection prevention and mitigation of cytokine release syndrome (CRS) during bispecific antibody step-up dosing.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss evolving treatment strategies for early relapse and relapsed/refractory multiple myeloma, focusing on recent evidence for T-cell redirecting therapies.

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss individualized treatment selection and sequencing in multiple myeloma as increasingly effective therapies expand available options.

Dr. Hans Lee and Dr. Prashant Kapoor discuss the evolving role of treatment duration and de-escalation in multiple myeloma, particularly for patients who achieve deep and sustained responses.

In this segment, Dr. Hans Lee and Dr. Muhamed Baljevic discuss treatment goals and evolving frontline strategies for multiple myeloma, with an emphasis on balancing disease control with long-term quality of life.

In this segment, Dr. Hans Lee introduces the rapidly evolving treatment landscape in multiple myeloma and outlines how advances in immunotherapy, quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping management across newly diagnosed and relapsed disease.

In this closing segment, Drs Paul Richardson and Hans Lee look ahead to how BCMA-directed bispecific antibodies may continue to evolve within an increasingly complex treatment landscape.

Drs Paul Richardson and Hans Lee discuss the evolving and often complex decisions around sequencing BCMA-directed therapies in multiple myeloma.

Drs Paul Richardson and Hans Lee address real-world strategies for managing cytokine release syndrome and how these considerations intersect with evolving treatment sequencing in multiple myeloma.

Hans Lee, MD, discusses the role of the CoMMit consortium as a collaborative forum shaping the future of multiple myeloma research.

Drs Paul Richardson and Hans Lee compare the three currently available BCMA-directed bispecific antibodies and discuss how differences in administration, logistics, and emerging data influence treatment selection in relapsed or refractory multiple myeloma.

Drs Paul Richardson and Hans Lee focus on practical infection mitigation strategies for patients receiving BCMA-directed bispecific antibodies, with particular emphasis on the proactive use of intravenous immunoglobulin.

Drs Paul Richardson and Hans Lee focus on the safety profile of linvoseltamab and how its clinical features translate into real-world and community-based practice.

Drs Paul Richardson and Hans Lee walk through the pivotal LINKER-MM1 trial that supported the July 2025 approval of linvoseltamab for patients with relapsed or refractory multiple myeloma after multiple prior lines of therapy.

Exploring the complexities of treating refractory myeloma patients, highlighting the significance of BCMA as a therapeutic target and innovative treatment options.

Explore the latest advancements in treating relapsed and refractory myeloma, including innovative therapies and their real-world applications.

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.